AGXT and cancer: In a recent publication in Nature, Muthusami et al.1 explore the effect of tumour serine restriction on sphingolipid heterogeneity, highlighting the promiscuity of SPT as a metabolic liability of cancer cells that can be exploited through diet or pharmacological means.